Saltar al contenido
Merck

Differences in antiproliferative effect of STAT3 inhibition in HCC cells with versus without HBV expression.

Biochemical and biophysical research communications (2015-04-23)
Yun Hong, Lin Zhou, Haiyang Xie, Weilin Wang, Shusen Zheng
RESUMEN

Chronic infection with hepatitis B virus (HBV) plays an important role in the etiology of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3) inactivation could inhibit the tumor growth of HCC. In this study, differential antiproliferative effect of STAT3 inhibition was observed with HBV-related HCC cells being more resistant than non-HBV-related HCC cells. Resistance of HBV-related HCC cells to STAT3 inhibition was positively correlated to the expression of HBV. Enhanced ERK activation after STAT3 blockade was detected in HBV-related HCC cells but not in non-HBV-related HCC cells. Combined ERK and STAT3 inhibition eliminates the discrepancy between the two types of HCC cells. Moderate reduced HBV expression was found after STAT3 inhibition. These findings disclose a discrepancy in cellular response to STAT3 inhibition between non-HBV-related and HBV-related HCC cells and underscore the complexity of antiproliferative effect of STAT3 inactivation in HBV-related HCC cells.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
G 418 disulfate salt solution, 50 mg/mL in H2O, 0.1 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
G 418 disulfate salt, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
2-Butanona, FCC, FG
Sigma-Aldrich
G 418 disulfate salt, potency: ≥720 μg per mg (dried basis)
Sigma-Aldrich
G 418 disulfate salt, suitable for plant cell culture, BioReagent
Sigma-Aldrich
S3I-201, ≥97% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human STAT3
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Stat3